Pharma Continues Its March To Academia, as Sanofi, UCB Strike Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.
You may also be interested in...
Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.
Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.
Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.